We are live on ! Find out more
QNCX icon

Quince Therapeutics

126 hedge funds and large institutions have $1.76B invested in Quince Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 27 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

79% more capital invested

Capital invested by funds: $982M → $1.76B (+$777M)

63% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 27

26% more funds holding

Funds holding: 100126 (+26)

23% more call options, than puts

Call options by funds: $133M | Put options by funds: $108M

0.01% more ownership

Funds ownership: 0.31%0.32% (+0.01%)

Holders
126
Holders Change
+26
Holders Change %
+26%
% of All Funds
2.21%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
34
Increased
44
Reduced
27
Closed
7
Calls
$133M
Puts
$108M
Net Calls
+$24.4M
Net Calls Change
+$7.53M

QNCX Hedge Fund Activity: Q3 2021 in Review

126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q3 2021, worth a combined $1.76B — up 79% from $982M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new QNCX positions and 7 closed out — a net gain of 27 holders — while 44 added to existing stakes and 27 trimmed.

The largest buyer was Capital International Investors, adding an estimated $19M. The largest seller was SC US (TTGP), exiting entirely with an estimated $29.7M sold.

  • 126 institutional investors held Quince Therapeutics (QNCX) as of Q3 2021, up from 100 in Q2 2021.
  • Funds reported $1.76B of Quince Therapeutics stock for Q3 2021, up 79% quarter-over-quarter.
  • 34 funds opened new Quince Therapeutics positions in Q3 2021 and 7 closed out, a net change of +27 holders.
  • The largest Quince Therapeutics buyer in Q3 2021 was Capital International Investors, an estimated $19M added.
  • The largest Quince Therapeutics seller in Q3 2021 was SC US (TTGP), an estimated $29.7M sold.

Based on aggregated 13F filings for Q3 2021.